Therefore, in the present study, we then further tested definitively whether B2-directed therapies, such as ablation of B2 cells with a B2 cell-depleting, anti-mouse CD23 antibody, could serve as a therapeutic target in atherosclerosis. The gene discussed is FCER2; the disease is atherosclerosis.